Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY 100 EV-to-EBIT is 30.98 as of Jul. 14, 2026, which is 6% below its 10-year median of 33.08. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,133.11 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 688 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 74.71% on this metric.
Eli Lilly and Co (XSWX:LLY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Eli Lilly and Co's Enterprise Value for the quarter that ended in Mar. 2026 was CHF682,242 Mil.
Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF28,523 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co EV-to-EBIT Related Terms
Eli Lilly and Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's EV-to-EBIT falls into.
Eli Lilly and Co's current Enterprise Value is CHF883,709 Mil.
Eli Lilly and Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF28,523 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a EV-to-EBIT of 30.98 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 33.08. Over the past decade, Eli Lilly and Co's EV-to-EBIT has ranged from 19.49 to 86.09. According to the industry distribution chart, Eli Lilly and Co ranks #514 out of 688 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Eli Lilly and Co's EV-to-EBIT too high?
Eli Lilly and Co's current EV-to-EBIT of 30.98 is near median its 10-year median of 33.08. Over the past 10 years, this metric has ranged from a low of 19.49 to a high of 86.09. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Eli Lilly and Co's value of 30.98 is 95.6% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #514 out of 688 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EV-to-EBIT compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #514 out of 688 companies for EV-to-EBIT. This places Eli Lilly and Co in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Eli Lilly and Co's value of 30.98 is 95.6% above this benchmark. Historically, Eli Lilly and Co's own EV-to-EBIT has ranged from 19.49 to 86.09 over the past decade. While the company's 10-year median is 33.08 vs. the industry median of 15.84, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current EV-to-EBIT of 30.98 is 95.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EV-to-EBIT is 30.98, which is near median its own 10-year median of 33.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,133.11, compared to a current price of CHF965.00 — trading 14.8% below its estimated fair value. The current EV-to-EBIT is 30.98, which is near median its 10-year median of 33.08 and 95.6% above the Drug Manufacturers industry median of 15.84. Eli Lilly and Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current EV-to-EBIT is 30.98 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF965.00 is trading 14.8% below its estimated GF Value™ of CHF1,133.11.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
EV-to-EBIT: 30.98 (near median its 10-year median of 33.08)
GF Value™: CHF1,133.11 vs. price of CHF965.00 (14.8% below fair value)
Industry Position: 95.6% above the Drug Manufacturers median (#514 of 688)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
